Dergi
/
Gelişim Biyolojisi
/
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
JoVE Journal
Gelişim Biyolojisi
Bu içeriği görüntülemek için JoVE aboneliği gereklidir.  Oturum açın veya ücretsiz deneme sürümünü başlatın.
JoVE Journal Gelişim Biyolojisi
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

8,169 Views

•

07:44 min

•

September 14, 2019

DOI:

10.3791/59432-v

DOI:
10.3791/59432-v

•

07:44 min
September 14, 2019

•

7 Views
, , , ,
1Medical College of Georgia,Augusta University

Özet

Automatically generated

Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.

Explore More Videos

CRISPR/Cas9DystrophinDuchenne Muscular DystrophyInduced Pluripotent Stem CellsMuscle Progenitor CellsGene EditingStem Cell TherapyAutologous CellsCongenital Diseases

Read Article

Cite this Article

Jin, Y., Shen, Y., Su, X., Weintraub, N., Tang, Y. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors. J. Vis. Exp. (151), e59432, doi:10.3791/59432 (2019).

Download .ris file

Copy

Share Video

.

Copy